GENEVA, April 21 /PRNewswire/ --
- First Drug in Europe Indicated for the Treatment of Hyperphenylalaninaemia (Hpa) due to Phenylketonuria (Pku) or Tetrahydrobiopterin (BH4) Deficiency, now Commercially Available in France, Germany and the United Kingdom
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Kuvan (sapropterin dihydrochloride), indicated for the treatment of hyperphenylalaninaemia (HPA) due to phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency, is now commercially available in Europe. Beginning with France, Germany and the United Kingdom, Kuvan will be rolled out in a total of thirteen European countries this year.